Filings & corporate actions
- 11 AugresultsResults · Q1 FY27 · consolidated and standalone-4.7%NSE
- 17 JulshareholdingShareholding · 30 Jun 20260.0%NSE
- 19 MayresultsResults · Q4 FY26 · consolidated and standalone-5.5%NSE
- 17 AprshareholdingShareholding · 31 Mar 2026+3.3%NSE
- 10 FebresultsResults · Q3 FY26 · consolidated and standalone+8.6%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-3.8%NSE
Reaction to results · all yearsrose on day 0 in 1 of 3 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 11 Aug 2026 | -4.7% | -3.0% | +3.0% | 2.6× |
| Q4 FY26 | 19 May 2026 | -5.5% | -6.9% | +11.3% | 2.3× |
| Q3 FY26 | 10 Feb 2026 | +8.6% | +8.6% | +4.5% | 18.4× |
| Average | -0.5% | -0.4% | +6.3% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSV| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVDelivery percentage
Over the last 20 sessions NEPHROPLUS settled 55.1% of its traded quantity, which is above average for an NSE equity. Its one-year average is 51.9%, so recent sessions are running 3.3 points higher than usual.
What delivery percentage measuresScan the whole market on delivery
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.49% | -5.85% | -10.22% | -3.79% | +20.04% | — |
Valuation
CSVOwnership
CSVQuarterly results · consolidated
CSV| Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|
| Revenue (₹ Cr) | 259.7 | 265.6 | 281.8 |
| YoY chg | — | — | — |
| Net profit (₹ Cr) | 32.2 | 30.4 | 32.0 |
| YoY chg | — | — | — |
| Net margin | 12.4% | 11.4% | 11.3% |
| EPS | 3.35 | 2.96 | 3.11 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 63.85% · public 36.15%- Promoter
- Public and others
- Promoter
- 63.85%
- Public
- 36.15%
- Promoter change
- 0.00 pp
- Filed
- 17 Jul 2026
- FII
- 8.78%
- DII
- 9.05%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV| Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|
| Revenue from operations | 259.7 | 265.6 | 281.8 | |
| Other income | 3.3 | 11.6 | 7.5 | |
| Total income | 263.0 | 277.2 | 289.2 | |
| Total expenses | 226.7 | 240.9 | 244.6 | |
| └ Finance costs | 6.0 | 3.2 | 2.2 | |
| └ Depreciation | 21.9 | 25.8 | 24.5 | |
| Profit before tax | 36.4 | 36.3 | 44.6 | |
| Tax expense | 4.1 | 2.8 | 9.1 | |
| Net profit | 32.2 | 30.4 | 32.0 | |
| EPS | 3.43 | 3.03 | 3.19 | |
| Net margin | 12.41% | 11.43% | 11.35% | |
| PBT margin | 14.00% | 13.67% | 15.83% | |
| Tax rate | 11.33% | 7.85% | 20.31% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.
3 quarters on file; a year-on-year comparison needs five.
NEPHROPLUS at a glance
- NEPHROPLUS closed at ₹634.55 on 6 Oct 2026, -0.49% on the day.
- Delivery was 64.8% of traded quantity on 6 Oct 2026, the 93rd percentile of its own 198 sessions with a reading (20-session average 55.1%, 1-year average 51.9%).
- Market capitalisation is ₹6,381 crore, with no positive trailing earnings for a P/E.
- Q1 FY27 results (consolidated, filed 11 Aug 2026): revenue ₹282 crore, net profit ₹32 crore; the price moved -4.7% on the first session after.
- Promoters held 63.85% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 18 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVPrices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Healthcare Services
CSV- APOLLOHOSPApollo Hospitals Enterprise Limited7,914.50-0.88%
- MAXHEALTHMax Healthcare Institute Limited902.50-1.58%
- FORTISFortis Healthcare Limited764.00+0.03%
- YATHARTHYatharth Hospital & Trauma Care Services Limited1,058.80+5.56%
- ASTERDMAster DM Quality Care Limited684.70-0.98%
- MANIPALHOSManipal Health Enterprises Limited690.50+3.52%
- LALPATHLABDr. Lal Path Labs Ltd.1,964.20-0.36%
- ARTEMISMEDArtemis Medicare Services Limited318.35-1.77%
- GKSLGujarat Kidney And Super Speciality Limited193.62+1.72%
- KIMSKrishna Institute of Medical Sciences Limited693.40-1.71%
- NHNarayana Hrudayalaya Ltd.1,723.80+0.08%
- MEDANTAGlobal Health Limited1,300.80-2.39%
All Healthcare Services stocks on the NSEAll Healthcare stocks on the NSE